Kampanjeplan Inhibrx, Inc.
Avansert tidsplan
Enkel graf
Om selskapet Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. flere detaljerIPO date | 2024-05-28 |
---|---|
Валюта | usd |
Сайт | https://inhibrx.com |
Цена ао | 30.85 |
Prisendring per dag: | 0% (30.85) |
---|---|
Prisendring per uke: | 0% (30.85) |
Prisendring per måned: | 0% (30.85) |
Prisendring over 3 måneder: | 0% (30.85) |
Prisendring over seks måneder: | 0% (30.85) |
Prisendring siden begynnelsen av året: | 0% (30.85) |
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
Veileder | Stillingstittel | Betaling | Fødselsår |
---|---|---|---|
Mr. Mark Paul Lappe | Founder, Chairman, President & CEO | 1967 (58 år) | |
Dr. Brendan P. Eckelman Ph.D. | Founder & Chief Scientific Officer | 1979 (46 år) | |
Mr. Quinn L. Deveraux | Founder | ||
Dr. Ashraf Amanullah | Executive VP & Chief Technical Operations Officer | 1968 (57 år) | |
Ms. Leah Pollema J.D. | VP, Corporate Secretary & General Counsel | ||
Dr. Charbel Helaihel Pharm.D. | Vice President of Marketing & Commercial Planning | ||
Mr. Jeffrey J. Jensen | Executive VP & Chief Clinical Operations Officer | ||
Mr. David Matly M.B.A. | Executive VP and Chief Commercial & Business Development Officer | ||
Dr. Carlos Bais Ph.D. | Executive Vice President of Translational Sciences | ||
Dr. Josep Garcia Ph.D. | EVP & Chief Clinical Development Officer |
Adresse: United States, La Jolla, 11025 North Torrey Pines Road - åpne i Google maps, åpne Yandex-kart
Nettsted: https://inhibrx.com
Nettsted: https://inhibrx.com